Liraglutide and Dapagliflozin Effects on MASLD Lipid Profile and Cardiovascular Risk Explored
Six-month effects of liraglutide and dapagliflozin on lipid profile, cardiovascular risk, and NT-proBNP levels in patients with metabolic dysfunction-associated steatotic liver disease.
Study Design
Population
Patients with MASLD (Metabolic dysfunction-associated steatotic liver disease) were studied.
Intervention
Liraglutide and dapagliflozin were administered for six months.
Outcome
The study assessed changes in lipid profiles, cardiovascular risk, and NT-proBNP levels.
Abstract
Liraglutide and dapagliflozin's six-month effects on lipid profiles, cardiovascular risk, and NT-proBNP in MASLD patients were assessed.